Evidence map›Paper›PMID 41214139›Full record

ArticleLeukemia2026

TGF-β-specific T cells are frequent in peripheral blood and bone-marrow from patients with myeloproliferative neoplasms.

Thomas Landkildehus Lisle, Morten Orebo Holmström, Maria Perez Penco, Josephine Hallundbæk Ruders, Caroline Hasselbalch Riley, Jacob Handlos Grauslund, Emilie Bülow Jensen, Anders Lindholm Sørensen, Vibe Skov, Lasse Kjær and 2 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Thomas Landkildehus LisleNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark.
Morten Orebo HolmströmNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark.
Maria Perez PencoNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark.
Josephine Hallundbæk RudersNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark.ORCID http://orcid.org/0009-0008-7900-0930
Caroline Hasselbalch RileyDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Jacob Handlos GrauslundNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark.
Emilie Bülow JensenNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark.
Anders Lindholm SørensenDepartment of Haematology, Zealand University Hospital, Roskilde, Denmark.
Vibe SkovDepartment of Haematology, Zealand University Hospital, Roskilde, Denmark.ORCID http://orcid.org/0000-0003-0097-7826
Lasse KjærDepartment of Haematology, Zealand University Hospital, Roskilde, Denmark.
Hans HasselbalchDepartment of Haematology, Zealand University Hospital, Roskilde, Denmark.
Mads Hald AndersenNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark. mads.hald.andersen@regionh.dk.ORCID http://orcid.org/0000-0002-2914-9605

Funding

Kræftens Bekæmpelse (Danish Cancer Society) R326-A18938
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.